Success Metrics

Clinical Success Rate
88.0%

Based on 22 completed trials

Completion Rate
88%(22/25)
Active Trials
0(0%)
Results Posted
86%(19 trials)
Terminated
3(12%)

Phase Distribution

Ph phase_4
3
12%
Ph phase_2
14
54%
Ph phase_1
6
23%
Ph not_applicable
3
12%

Phase Distribution

6

Early Stage

14

Mid Stage

3

Late Stage

Phase Distribution26 total trials
Phase 1Safety & dosage
6(23.1%)
Phase 2Efficacy & side effects
14(53.8%)
Phase 4Post-market surveillance
3(11.5%)
N/ANon-phased studies
3(11.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.6%

22 of 26 finished

Non-Completion Rate

15.4%

4 ended early

Currently Active

0

trials recruiting

Total Trials

26

all time

Status Distribution
Completed(22)
Terminated(4)

Detailed Status

Completed22
Terminated3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
26
Active
0
Success Rate
88.0%
Most Advanced
Phase 4

Trials by Phase

Phase 16 (23.1%)
Phase 214 (53.8%)
Phase 43 (11.5%)
N/A3 (11.5%)

Trials by Status

completed2285%
terminated312%
withdrawn14%

Recent Activity

Clinical Trials (26)

Showing 20 of 26 trialsScroll for more
NCT03229408Phase 2

Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction

Completed
NCT02936843Phase 2

Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy

Completed
NCT03277573Phase 1

Salsalate in Patients Mild to Moderate Alzheimer's Disease

Completed
NCT01977417Phase 2

Inflammation Inhibition in Prediabetic Humans

Terminated
NCT04146038Phase 2

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Completed
NCT03816488Phase 1

Oral Peri-operative TIming of Metformin (or) Salsalate to Improve Non-cardiac Surgery Glucose Control

Withdrawn
NCT01182727Not Applicable

Salsalate for Insulin Resistance in Schizophrenia

Completed
NCT02422485Phase 1

A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy

Completed
NCT00330733Phase 2

Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

Completed
NCT03222206Phase 4

The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease

Completed
NCT00624923Phase 2

Targeting Inflammation Using Salsalate in CardioVascular Disease

Completed
NCT00258128Phase 1

Effect of Salicylate on Glucose Metabolism in Insulin Resistance States

Completed
NCT00392678Phase 2

Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

Completed
NCT02406586Not Applicable

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

Completed
NCT01775865Phase 2

Targeting Inflammation to Treat Cardiovascular Aging

Completed
NCT01578486Phase 4

Salsalate as an Adjunctive Treatment for Patients With Schizophrenia

Completed
NCT00258115Phase 2

The Study of Inflammation on Blood Glucose Levels in Obese People

Completed
NCT00799643Phase 2

Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II

Completed
NCT00760019Phase 2

Inflammation and Vascular Function in Atherosclerosis

Completed
NCT00553995Phase 1

Effect of Salsalate on Bed Rest-Induced Vascular Dysfunction

Completed

Drug Details

Intervention Type
DRUG
Total Trials
26